CU20170039A7 - Método de purificación del anticuerpo humanizado 9e4 - Google Patents
Método de purificación del anticuerpo humanizado 9e4Info
- Publication number
- CU20170039A7 CU20170039A7 CUP2017000039A CU20170039A CU20170039A7 CU 20170039 A7 CU20170039 A7 CU 20170039A7 CU P2017000039 A CUP2017000039 A CU P2017000039A CU 20170039 A CU20170039 A CU 20170039A CU 20170039 A7 CU20170039 A7 CU 20170039A7
- Authority
- CU
- Cuba
- Prior art keywords
- solid phase
- impurities
- antibody
- perform
- respect
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Analytical Chemistry (AREA)
- Inorganic Chemistry (AREA)
Abstract
Un método de purificación de un anticuerpo 9E4 humanizado caracterizado en que comprende la realización de una cromatografía en fase sólida de proteína A, en donde el anticuerpo 9E4 se une preferentemente a la fase sólida con respecto a las impurezas; la realización de la cromatografia de intercarnbio aniónico de fase sólida, en donde el anticuerpo 9E4 eluye preferentemente de la fase sólida con respecto a las impurezas; realizar una cromatografía de intercambio catiónico en fase sólida, en donde el anticuerpo 9E4 se une preferentemente a la fase sólida con respecto a las impurezas; realizar una inactivación viral y/o etapa de eliminación; realizar una etapa de filtración; y realizar una etapa de concentración y resuspensión.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361843011P | 2013-07-04 | 2013-07-04 | |
US201461979886P | 2014-04-15 | 2014-04-15 | |
PCT/IB2014/062806 WO2015001504A2 (en) | 2013-07-04 | 2014-07-03 | Antibody formulations and methods |
Publications (1)
Publication Number | Publication Date |
---|---|
CU20170039A7 true CU20170039A7 (es) | 2017-06-05 |
Family
ID=51355583
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CUP2017000039A CU20170039A7 (es) | 2013-07-04 | 2014-07-03 | Método de purificación del anticuerpo humanizado 9e4 |
CUP2016000001A CU20160001A7 (es) | 2013-07-04 | 2016-01-04 | Una formulación farmacéutica que comprende una versión quimérica, una versión de fragmentos no humanos o humanizados del anticuerpo 9e4 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CUP2016000001A CU20160001A7 (es) | 2013-07-04 | 2016-01-04 | Una formulación farmacéutica que comprende una versión quimérica, una versión de fragmentos no humanos o humanizados del anticuerpo 9e4 |
Country Status (18)
Country | Link |
---|---|
US (2) | US10513555B2 (es) |
EP (2) | EP3524264A1 (es) |
JP (3) | JP6404338B2 (es) |
KR (1) | KR20160030247A (es) |
CN (1) | CN105492019B (es) |
AU (1) | AU2014285719A1 (es) |
CA (1) | CA2917097C (es) |
CL (1) | CL2015003801A1 (es) |
CU (2) | CU20170039A7 (es) |
ES (1) | ES2704440T3 (es) |
HK (1) | HK1223544A1 (es) |
IL (1) | IL243425A0 (es) |
MX (1) | MX2016000201A (es) |
PE (1) | PE20160868A1 (es) |
PH (1) | PH12015502788A1 (es) |
RU (1) | RU2016103079A (es) |
SG (1) | SG11201510601TA (es) |
WO (1) | WO2015001504A2 (es) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104334184B (zh) | 2011-10-28 | 2017-12-29 | 普罗典娜生物科学有限公司 | 识别α‑突触核蛋白的人源化抗体 |
CA2863953A1 (en) | 2012-01-27 | 2013-08-01 | Neotope Biosciences Limited | Humanized antibodies that recognize alpha-synuclein |
UA118441C2 (uk) | 2012-10-08 | 2019-01-25 | Протена Біосаєнсиз Лімітед | Антитіло, що розпізнає альфа-синуклеїн |
US10513555B2 (en) | 2013-07-04 | 2019-12-24 | Prothena Biosciences Limited | Antibody formulations and methods |
WO2015155694A1 (en) | 2014-04-08 | 2015-10-15 | Prothena Biosciences Limited | Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein |
GB201512203D0 (en) | 2015-07-13 | 2015-08-19 | Lundbeck & Co As H | Agents,uses and methods |
EP3334747B1 (en) | 2015-08-13 | 2023-09-27 | Amgen Inc. | Charged depth filtration of antigen-binding proteins |
CA2999079A1 (en) * | 2015-09-28 | 2017-04-06 | Jiangsu Hengrui Medicine Co., Ltd. | Stable anti-pd-1 antibody pharmaceutical preparation and application thereof in medicine |
CN105127166A (zh) * | 2015-09-29 | 2015-12-09 | 中国华能集团清洁能源技术研究院有限公司 | 行走组件及具有其的光伏组件清洁装置 |
SG11201810429UA (en) * | 2016-06-27 | 2018-12-28 | Morphosys Ag | Anti-cd19 antibody formulations |
WO2018091444A1 (en) * | 2016-11-15 | 2018-05-24 | H. Lundbeck A/S | Agents, uses and methods for the treatment of synucleinopathy |
WO2018109058A1 (en) | 2016-12-16 | 2018-06-21 | H. Lundbeck A/S | Agents, uses and methods |
US10364286B2 (en) | 2016-12-22 | 2019-07-30 | H. Lundbeck A/S | Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation |
KR102573778B1 (ko) | 2017-02-17 | 2023-08-31 | 브리스톨-마이어스 스큅 컴퍼니 | 알파-시뉴클레인에 대한 항체 및 그의 용도 |
CA3076313A1 (en) * | 2017-09-28 | 2019-04-04 | Prothena Biosciences Limited | Dosing regimes for treatment of synucleinopathies |
JP6831861B2 (ja) | 2019-01-25 | 2021-02-17 | 株式会社Grin | 歯科用測定器具、測定方法、及びアタッチメント器具 |
MA55033A (fr) | 2019-02-18 | 2021-12-29 | Lilly Co Eli | Formulation d'anticorps thérapeutique |
EP3786174A1 (en) * | 2019-08-27 | 2021-03-03 | Ichnos Sciences SA | Methods for antibody purification |
GB2587228B (en) * | 2019-09-20 | 2021-10-27 | Protein Ark Ltd | Biological sample purification apparatus, use of the same, and systems comprising the same |
CN116348487A (zh) | 2020-07-23 | 2023-06-27 | 欧萨尔普罗席纳有限公司 | 抗淀粉样β抗体 |
CN114516914B (zh) * | 2020-11-19 | 2023-04-28 | 东莞市朋志生物科技有限公司 | 抗n末端脑钠肽前体的抗体和检测n末端脑钠肽前体的试剂和试剂盒 |
CN117915952A (zh) * | 2021-09-16 | 2024-04-19 | H.隆德贝克有限公司 | 用于治疗突触核蛋白病的组合物和方法 |
Family Cites Families (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
IE64738B1 (en) | 1990-03-20 | 1995-09-06 | Akzo Nv | Stabilized gonadotropin containing preparations |
DK0590058T3 (da) | 1991-06-14 | 2004-03-29 | Genentech Inc | Humaniseret heregulin-antistof |
US5786464C1 (en) | 1994-09-19 | 2012-04-24 | Gen Hospital Corp | Overexpression of mammalian and viral proteins |
AU695129B2 (en) | 1995-02-06 | 1998-08-06 | Genetics Institute, Llc | Formulations for IL-12 |
DE19539493A1 (de) | 1995-10-24 | 1997-04-30 | Thomae Gmbh Dr K | Starker homologer Promotor aus Hamster |
US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
US6114148C1 (en) | 1996-09-20 | 2012-05-01 | Gen Hospital Corp | High level expression of proteins |
US5888809A (en) | 1997-05-01 | 1999-03-30 | Icos Corporation | Hamster EF-1α transcriptional regulatory DNA |
EP1453000B1 (en) | 1999-02-05 | 2010-12-01 | Samsung Electronics Co., Ltd. | Image texture retrieving method and apparatus thereof |
EP1355919B1 (en) | 2000-12-12 | 2010-11-24 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
MXPA05000511A (es) | 2001-07-12 | 2005-09-30 | Jefferson Foote | Anticuepros super humanizados. |
US7657380B2 (en) | 2003-12-04 | 2010-02-02 | Xencor, Inc. | Methods of generating variant antibodies with increased host string content |
CN100577164C (zh) | 2002-04-09 | 2010-01-06 | 弗拉梅技术公司 | 可改进释放阿莫西林的微囊含水混悬液形式的口服药物制剂 |
WO2004039234A2 (en) | 2002-05-13 | 2004-05-13 | Alexion Pharmaceuticals, Inc. | Humanized antibodies against the venezuelan equine encephalitis virus |
US9034337B2 (en) | 2003-10-31 | 2015-05-19 | Prothena Biosciences Limited | Treatment and delay of outset of synucleinopathic and amyloidogenic disease |
US8506959B2 (en) | 2002-11-01 | 2013-08-13 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
US20080014194A1 (en) | 2003-10-31 | 2008-01-17 | Elan Pharmaceuticals, Inc. | Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease |
TW200509968A (en) | 2002-11-01 | 2005-03-16 | Elan Pharm Inc | Prevention and treatment of synucleinopathic disease |
MXPA05005481A (es) | 2002-11-29 | 2005-07-25 | Boehringer Ingelheim Pharma | Nuevos genes de la fosfotransferasa de neomicina y procedimiento para la seleccion de celulas recombinantes de produccion elevada. |
CN1798575A (zh) | 2003-04-04 | 2006-07-05 | 健泰科生物技术公司 | 高浓度抗体和蛋白制剂 |
US7358331B2 (en) | 2003-05-19 | 2008-04-15 | Elan Pharmaceuticals, Inc. | Truncated fragments of alpha-synuclein in Lewy body disease |
DE10338531A1 (de) | 2003-08-19 | 2005-04-07 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Reklonierung von Produktionszellen |
US7674599B2 (en) | 2003-11-08 | 2010-03-09 | Elan Pharmaceuticals, Inc. | Methods of using antibodies to detect alpha-synuclein in fluid samples |
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
DE602005014805D1 (de) | 2004-11-10 | 2009-07-16 | Boehringer Ingelheim Pharma | Verwendung von durchflusszytometrischer analyse zur optimierung von zellbankingstrategien für cho-zellen |
US20080300204A1 (en) | 2005-07-19 | 2008-12-04 | University Of Rochester | Alpha-Synuclein Antibodies and Methods Related Thereto |
US7662930B2 (en) * | 2005-12-06 | 2010-02-16 | Amgen Inc. | Polishing steps used in multi-step protein purification processes |
CL2007002070A1 (es) | 2006-07-14 | 2008-02-08 | Ac Immune S A Genentech Inc | Anticuerpo quimerico o humanizado, o fragmentos de ellos, que se adhieren especificamente a por lo menos un epitopo en la proteina beta-amiloide; molecula de acido nucleico que lo codifica; composicion que lo comprende; su uso para tratar enfermedade |
US20080124760A1 (en) | 2006-07-26 | 2008-05-29 | Barbara Enenkel | Regulatory Nucleic Acid Elements |
MX2009009080A (es) | 2007-02-23 | 2009-11-02 | Schering Corp | Anticuerpos anti-interleucina-23p19 manipulados por ingenieria genetica. |
DK3067066T3 (da) | 2007-02-23 | 2019-05-20 | Prothena Biosciences Ltd | Forebyggelse og behandling af synukleinopatisk og amyloidogenisk sygdom |
US8147833B2 (en) * | 2007-02-23 | 2012-04-03 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
TWI419902B (zh) | 2007-03-02 | 2013-12-21 | 百靈佳殷格翰製藥公司 | 蛋白質產製之改良 |
CA2681743A1 (en) * | 2007-03-22 | 2008-09-25 | Imclone Llc | Stable antibody formulations |
CA2681341A1 (en) | 2007-03-22 | 2008-09-25 | Genentech, Inc. | Apoptotic anti-ige antibodies |
EP2031064A1 (de) | 2007-08-29 | 2009-03-04 | Boehringer Ingelheim Pharma GmbH & Co. KG | Verfahren zur Steigerung von Proteintitern |
JP5490714B2 (ja) * | 2007-11-28 | 2014-05-14 | メディミューン,エルエルシー | タンパク質製剤 |
BRPI0820819B1 (pt) | 2007-12-21 | 2021-06-08 | F. Hoffmann-La Roche Ag | formulação de anticorpos humanizados b-ly 1 e seu uso |
AU2008345022B2 (en) | 2007-12-28 | 2014-11-06 | Prothena Biosciences Limited | Treatment and prophylaxis of amyloidosis |
LT2282758T (lt) | 2008-04-29 | 2019-03-12 | Bioarctic Ab | Antikūnai ir vakcinos, skirti su alfa sinukleinu susijusių sutrikimų gydymo ir diagnostiniams metodams |
WO2009141239A1 (en) * | 2008-05-20 | 2009-11-26 | F. Hoffmann-La Roche Ag | A pharmaceutical formulation comprising an antibody against ox40l, uses thereof |
US20120276019A1 (en) | 2008-07-25 | 2012-11-01 | Diamedica Inc. | Tissue kallikrein for the treatment of parkinson's disease |
US8940276B2 (en) | 2008-12-19 | 2015-01-27 | Biogen Idec International Neuroscience Gmbh | Human anti-alpha-synuclein antibodies |
EP2459212B1 (en) | 2009-07-28 | 2018-03-14 | Shire Human Genetic Therapies, Inc. | Compositions and methods for treating gaucher disease |
AR078161A1 (es) | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento. |
WO2011090720A2 (en) | 2009-12-29 | 2011-07-28 | Dr. Reddy's Laboratories Ltd | Purification of proteins |
EP2366714A1 (en) | 2010-03-03 | 2011-09-21 | Dr. Rentschler Holding GmbH & Co. KG | Naturally occuring autoantibodies against alpha-synuclein that inhibit the aggregation and cytotoxicity of alpha-synuclein |
TW201134488A (en) | 2010-03-11 | 2011-10-16 | Ucb Pharma Sa | PD-1 antibodies |
WO2011127324A2 (en) | 2010-04-08 | 2011-10-13 | JN Biosciences, LLC | Antibodies to cd122 |
TWI526161B (zh) | 2010-06-10 | 2016-03-21 | 亞培公司 | 包含鈣hmb及可溶性蛋白質之實質上透明營養液 |
JP6158511B2 (ja) | 2010-06-11 | 2017-07-05 | 協和発酵キリン株式会社 | 抗tim−3抗体 |
SI2593128T1 (en) | 2010-07-15 | 2018-08-31 | Adheron Therapeutics, Inc. | Humanized antibodies targeting the EC1 Kaderina-11 domain and associated compositions and procedures |
RU2610667C2 (ru) * | 2010-10-11 | 2017-02-14 | Эббви Бахамаз Лтд., | Способ очистки белков |
CA2825791A1 (en) | 2011-02-07 | 2012-08-16 | Neotope Biosciences Limited | Apoe immunotherapy |
WO2012160536A1 (en) | 2011-05-26 | 2012-11-29 | Dr Reddy's Laboratories Limited | Antibody purification |
CN103764166B (zh) | 2011-06-22 | 2017-10-24 | 通用医疗公司 | 蛋白质病的治疗 |
AR086823A1 (es) * | 2011-06-30 | 2014-01-22 | Genentech Inc | Formulaciones de anticuerpo anti-c-met, metodos |
EP4088736A1 (en) * | 2011-10-25 | 2022-11-16 | Prothena Biosciences Limited | Humanized anti-amyloid antibody formulations and methods |
CN104334184B (zh) | 2011-10-28 | 2017-12-29 | 普罗典娜生物科学有限公司 | 识别α‑突触核蛋白的人源化抗体 |
MX363226B (es) | 2011-10-31 | 2019-03-15 | Genentech Inc | Formulaciones de anticuerpos. |
CA2863953A1 (en) | 2012-01-27 | 2013-08-01 | Neotope Biosciences Limited | Humanized antibodies that recognize alpha-synuclein |
US9216219B2 (en) * | 2012-06-12 | 2015-12-22 | Novartis Ag | Anti-BAFFR antibody formulation |
KR102036262B1 (ko) | 2012-08-29 | 2019-10-24 | 에프. 호프만-라 로슈 아게 | 혈액 뇌 장벽 셔틀 |
US8925815B2 (en) | 2012-09-05 | 2015-01-06 | Symbol Technologies, Inc. | Checkout system for and method of preventing a customer-operated accessory reader facing a bagging area from imaging targets on products passed through a clerk-operated workstation to the bagging area |
UA118441C2 (uk) | 2012-10-08 | 2019-01-25 | Протена Біосаєнсиз Лімітед | Антитіло, що розпізнає альфа-синуклеїн |
US10513555B2 (en) | 2013-07-04 | 2019-12-24 | Prothena Biosciences Limited | Antibody formulations and methods |
WO2015155694A1 (en) | 2014-04-08 | 2015-10-15 | Prothena Biosciences Limited | Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein |
US10084674B2 (en) | 2015-09-09 | 2018-09-25 | International Business Machines Corporation | Virtual desktop operation and data continuity preservation |
-
2014
- 2014-07-02 US US14/322,797 patent/US10513555B2/en active Active
- 2014-07-03 EP EP18212531.0A patent/EP3524264A1/en active Pending
- 2014-07-03 JP JP2016522950A patent/JP6404338B2/ja active Active
- 2014-07-03 KR KR1020167003163A patent/KR20160030247A/ko not_active Application Discontinuation
- 2014-07-03 WO PCT/IB2014/062806 patent/WO2015001504A2/en active Application Filing
- 2014-07-03 CA CA2917097A patent/CA2917097C/en active Active
- 2014-07-03 CN CN201480047476.9A patent/CN105492019B/zh active Active
- 2014-07-03 RU RU2016103079A patent/RU2016103079A/ru not_active Application Discontinuation
- 2014-07-03 CU CUP2017000039A patent/CU20170039A7/es unknown
- 2014-07-03 AU AU2014285719A patent/AU2014285719A1/en not_active Abandoned
- 2014-07-03 EP EP14752412.8A patent/EP3016677B1/en active Active
- 2014-07-03 SG SG11201510601TA patent/SG11201510601TA/en unknown
- 2014-07-03 PE PE2015002708A patent/PE20160868A1/es not_active Application Discontinuation
- 2014-07-03 ES ES14752412T patent/ES2704440T3/es active Active
- 2014-07-03 MX MX2016000201A patent/MX2016000201A/es unknown
-
2015
- 2015-12-16 PH PH12015502788A patent/PH12015502788A1/en unknown
- 2015-12-31 CL CL2015003801A patent/CL2015003801A1/es unknown
- 2015-12-31 IL IL243425A patent/IL243425A0/en unknown
-
2016
- 2016-01-04 CU CUP2016000001A patent/CU20160001A7/es unknown
- 2016-10-12 HK HK16111756.3A patent/HK1223544A1/zh unknown
-
2018
- 2018-09-12 JP JP2018170393A patent/JP6854266B2/ja active Active
-
2019
- 2019-11-01 US US16/672,330 patent/US20200140534A1/en not_active Abandoned
-
2020
- 2020-10-23 JP JP2020177954A patent/JP2021020941A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
HK1223544A1 (zh) | 2017-08-04 |
KR20160030247A (ko) | 2016-03-16 |
CA2917097A1 (en) | 2015-01-08 |
SG11201510601TA (en) | 2016-01-28 |
WO2015001504A3 (en) | 2015-08-06 |
JP6404338B2 (ja) | 2018-10-10 |
PE20160868A1 (es) | 2016-09-24 |
WO2015001504A2 (en) | 2015-01-08 |
RU2016103079A (ru) | 2017-08-07 |
EP3016677B1 (en) | 2018-12-19 |
CU20160001A7 (es) | 2016-08-31 |
JP2019011339A (ja) | 2019-01-24 |
IL243425A0 (en) | 2016-03-31 |
US10513555B2 (en) | 2019-12-24 |
US20150079074A1 (en) | 2015-03-19 |
CN105492019B (zh) | 2020-02-11 |
JP2016534052A (ja) | 2016-11-04 |
PH12015502788A1 (en) | 2016-03-21 |
EP3524264A1 (en) | 2019-08-14 |
JP2021020941A (ja) | 2021-02-18 |
US20200140534A1 (en) | 2020-05-07 |
JP6854266B2 (ja) | 2021-04-07 |
CL2015003801A1 (es) | 2016-07-15 |
MX2016000201A (es) | 2016-05-31 |
CN105492019A (zh) | 2016-04-13 |
EP3016677A2 (en) | 2016-05-11 |
CA2917097C (en) | 2022-05-03 |
ES2704440T3 (es) | 2019-03-18 |
AU2014285719A1 (en) | 2016-01-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CU20170039A7 (es) | Método de purificación del anticuerpo humanizado 9e4 | |
CY1124921T1 (el) | Μεθοδοι για την εκχυλιση και τον καθαρισμο μη μετουσιωμενων πρωτεϊνων | |
AR108800A1 (es) | Purificación de anticuerpos multiespecíficos | |
SG10201902924RA (en) | Antibodies that bind ebola glycoprotein and uses thereof | |
EA201690314A1 (ru) | Анти-garp-белок и его применения | |
EA202092435A2 (ru) | Моноклональные антитела против bcma | |
PE20200012A1 (es) | Anticuerpos mono- y biespecificos que se unen al factor de coagulacion ix y al factor de coagulacion x | |
MX2016016886A (es) | Anticuerpos anti-axl. | |
MX2015015482A (es) | Proceso continuo de multiples etapas para purificar anticuerpos. | |
PH12017500915A1 (en) | Cd47 antibodies, methods, and uses | |
PE20170665A1 (es) | Anticuerpos anti-tau humanizados | |
WO2015191911A3 (en) | Protein enriched microvesicles and methods of making and using the same | |
EA201791029A1 (ru) | Антитела против интерлейкина-33 и их применение | |
CL2019000082A1 (es) | Anticuerpos específicos para la tau hiperfosforilada y sus métodos de uso. | |
CL2015002756A1 (es) | Moléculas fc biespecíficas | |
ES2687282T3 (es) | Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos | |
EA201591806A1 (ru) | Лечение и профилактика острой почечной недостаточности с применением анти-альфа-v-бета-5 антител | |
EA201400875A1 (ru) | Антитела к cd47 и способы их применения | |
BR112016016916A8 (pt) | uso de um anticorpo que se liga à calicreína plasmática ativa para tratamento de angiodema hereditário (hae) | |
EP3831802A3 (fr) | Procede de purification de la vanilline naturelle | |
PE20161032A1 (es) | Anticuerpos anti-tau(ps422) humanizados y metodos de utilizacion | |
CY1120824T1 (el) | Μεθοδοι αυξησης περιεχομενου μαννοζης ανασυνδυασμενων πρωτεϊνων | |
CO2017010631A2 (es) | Método para purificación de proteína | |
EA201600429A1 (ru) | Способ очистки 2,5-дихлорфенола | |
GEP20227382B (en) | Anti-coagulation factor xi antibodies |